Published in Vaccine Weekly, March 6th, 2002
The main objectives are to see if the candidate vaccine is safe and whether the human immune system responds to it.
The first human clinical trial of GSK Biologicals' candidate HIV vaccine will be conducted in collaboration with the HIV Vaccine Trials Network (HVTN) in the U.S., following the encouraging results from rhesus monkey efficacy studies and other clinical studies on novel adjuvants. The HVTN is sponsored by the National...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.